+286.6%
DOCN vs MRNA
+444.4%
-157.8%
-42.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.7% | -3.4% | +8.1% | +4.7% |
| 7D | +26.5% | -10.1% | +36.6% | +26.3% |
| 30D | +2.3% | +126.7% | -124.5% | +4.5% |
| 3M | -21.2% | +184.1% | -205.3% | -22.9% |
| 6M | +130.6% | +143.3% | -12.7% | +129.4% |
| YTD | +175.7% | +359.9% | -184.1% | +143.8% |
| 1Y | +286.6% | +454.2% | -167.6% | +221.5% |
| All | +286.6% | +444.4% | -157.8% | +221.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling